Recombinant adeno-associated viruses (rAAVs) are commonly used vehicles for in vivo gene transfer. However, the tropism repertoire of naturally occurring AAVs is limited. As such, we are developing a capsid selection method that enables the development of AAV capsids that more efficiently transduce the cell of interest. By creating a novel AAV capsid for individual human cells, we are providing the best vehicle to deliver gene therapy to that cell. Moreover, capturing the IP on the other sequences allows for full protection on human delivery sequences.